BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schneider SA, Alcalay RN. Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease. J Neurol 2020;267:860-9. [PMID: 31974807 DOI: 10.1007/s00415-020-09705-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Diaz-Ortiz ME, Seo Y, Posavi M, Carceles Cordon M, Clark E, Jain N, Charan R, Gallagher MD, Unger TL, Amari N, Skrinak RT, Davila-Rivera R, Brody EM, Han N, Zack R, Van Deerlin VM, Tropea TF, Luk KC, Lee EB, Weintraub D, Chen-Plotkin AS. GPNMB confers risk for Parkinson's disease through interaction with α-synuclein. Science 2022;377:eabk0637. [PMID: 35981040 DOI: 10.1126/science.abk0637] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Niotis K, West AB, Saunders-Pullman R. Who to Enroll in Parkinson Disease Prevention Trials? The Case for Genetically At-Risk Cohorts. Neurology 2022;99:10-8. [PMID: 35970585 DOI: 10.1212/WNL.0000000000200812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Ochenkowska K, Herold A, Samarut É. Zebrafish Is a Powerful Tool for Precision Medicine Approaches to Neurological Disorders. Front Mol Neurosci 2022;15:944693. [PMID: 35875659 DOI: 10.3389/fnmol.2022.944693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Schalkamp AK, Rahman N, Monzón-Sandoval J, Sandor C. Deep phenotyping for precision medicine in Parkinson's disease. Dis Model Mech 2022;15:dmm049376. [PMID: 35647913 DOI: 10.1242/dmm.049376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Farrow SL, Cooper AA, O'Sullivan JM. Redefining the hypotheses driving Parkinson's diseases research. NPJ Parkinsons Dis 2022;8:45. [PMID: 35440633 DOI: 10.1038/s41531-022-00307-w] [Reference Citation Analysis]
6 Schiff L, Migliori B, Chen Y, Carter D, Bonilla C, Hall J, Fan M, Tam E, Ahadi S, Fischbacher B, Geraschenko A, Hunter CJ, Venugopalan S, DesMarteau S, Narayanaswamy A, Jacob S, Armstrong Z, Ferrarotto P, Williams B, Buckley-Herd G, Hazard J, Goldberg J, Coram M, Otto R, Baltz EA, Andres-Martin L, Pritchard O, Duren-Lubanski A, Daigavane A, Reggio K, Nelson PC, Frumkin M, Solomon SL, Bauer L, Aiyar RS, Schwarzbach E, Noggle SA, Monsma FJ Jr, Paull D, Berndl M, Yang SJ, Johannesson B; NYSCF Global Stem Cell Array® Team. Integrating deep learning and unbiased automated high-content screening to identify complex disease signatures in human fibroblasts. Nat Commun 2022;13:1590. [PMID: 35338121 DOI: 10.1038/s41467-022-28423-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
7 Mari Z, Mestre TA. The Disease Modification Conundrum in Parkinson’s Disease: Failures and Hopes. Front Aging Neurosci 2022;14:810860. [DOI: 10.3389/fnagi.2022.810860] [Reference Citation Analysis]
8 Gérard M, Bayot M, Derambure P, Dujardin K, Defebvre L, Betrouni N, Delval A. EEG-based functional connectivity and executive control in patients with Parkinson’s disease and freezing of gait. Clinical Neurophysiology 2022. [DOI: 10.1016/j.clinph.2022.01.128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Pang SY, Lo RCN, Ho PW, Liu H, Chang EES, Leung C, Malki Y, Choi ZY, Wong WY, Kung MH, Ramsden DB, Ho S. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease. Transl Neurodegener 2022;11. [DOI: 10.1186/s40035-022-00281-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Cao X, Yang F, Zheng J, Wang X, Huang Q. Aberrant Structure MRI in Parkinson’s Disease and Comorbidity with Depression Based on Multinomial Tensor Regression Analysis. JPM 2022;12:89. [DOI: 10.3390/jpm12010089] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Peterschmitt MJ, Saiki H, Hatano T, Gasser T, Isaacson SH, Gaemers SJM, Minini P, Saubadu S, Sharma J, Walbillic S, Alcalay RN, Cutter G, Hattori N, Höglinger GU, Marek K, Schapira AHV, Scherzer CR, Simuni T, Giladi N, Sardi SP, Fischer TZ; MOVES-PD Investigators. Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. J Parkinsons Dis 2022;12:557-70. [PMID: 34897099 DOI: 10.3233/JPD-212714] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
12 Memou A, Dimitrakopoulos L, Kedariti M, Kentros M, Lamprou A, Petropoulou-Vathi L, Valkimadi PE, Rideout HJ. Defining (and blocking) neuronal death in Parkinson's disease: Does it matter what we call it? Brain Res 2021;1771:147639. [PMID: 34492263 DOI: 10.1016/j.brainres.2021.147639] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Eisenberg DP, Lopez G, Gregory MD, Berman KF, Sidransky E. Comparison of Transcranial Sonography and [18 F]-Fluorodopa PET Imaging in GBA1 Mutation Carriers. Mov Disord 2021. [PMID: 34762337 DOI: 10.1002/mds.28852] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Surface M, Balwani M, Waters C, Haimovich A, Gan-Or Z, Marder KS, Hsieh T, Song L, Padmanabhan S, Hsieh F, Merchant KM, Alcalay RN. Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease. Mov Disord 2021. [PMID: 34741486 DOI: 10.1002/mds.28846] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
15 Srinivasan E, Chandrasekhar G, Chandrasekar P, Anbarasu K, Vickram AS, Karunakaran R, Rajasekaran R, Srikumar PS. Alpha-Synuclein Aggregation in Parkinson's Disease. Front Med (Lausanne) 2021;8:736978. [PMID: 34733860 DOI: 10.3389/fmed.2021.736978] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
16 Vieira SRL, Schapira AHV. Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways. Free Radic Biol Med 2021;175:42-55. [PMID: 34450264 DOI: 10.1016/j.freeradbiomed.2021.08.230] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
17 He JM, Wu ZB, Cai NQ, Lin Y. Levodopa-Induced Ocular Dyskinesia in an Early-Onset Parkinson Disease Patient With GBA Mutation. Clin Neuropharmacol 2021;44:201-4. [PMID: 34654015 DOI: 10.1097/WNF.0000000000000484] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Lungu C, Cedarbaum JM, Dawson TM, Dorsey ER, Faraco C, Federoff HJ, Fiske B, Fox R, Goldfine AM, Kieburtz K, Macklin EA, Matthews H, Rafaloff G, Saunders-Pullman R, Schor NF, Schwarzschild MA, Sieber BA, Simuni T, Surmeier DJ, Tamiz A, Werner MH, Wright CB, Wyse R. Seeking progress in disease modification in Parkinson disease. Parkinsonism Relat Disord 2021;90:134-41. [PMID: 34561166 DOI: 10.1016/j.parkreldis.2021.09.006] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
19 Riboldi GM, Frattini E, Monfrini E, Frucht SJ, Fonzo AD. A Practical Approach to Early-Onset Parkinsonism. J Parkinsons Dis 2021. [PMID: 34569973 DOI: 10.3233/JPD-212815] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Axtman AD. Characterizing the role of the dark kinome in neurodegenerative disease - A mini review. Biochim Biophys Acta Gen Subj 2021;1865:130014. [PMID: 34547390 DOI: 10.1016/j.bbagen.2021.130014] [Reference Citation Analysis]
21 Mishima T, Fujioka S, Morishita T, Inoue T, Tsuboi Y. Personalized Medicine in Parkinson's Disease: New Options for Advanced Treatments. J Pers Med 2021;11:650. [PMID: 34357117 DOI: 10.3390/jpm11070650] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Rosca EC, Tudor R, Cornea A, Simu M. Parkinson's Disease in Romania: A Scoping Review. Brain Sci 2021;11:709. [PMID: 34071802 DOI: 10.3390/brainsci11060709] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 Zimran A, Ruchlemer R, Revel-Vilk S. A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact. Hematology Am Soc Hematol Educ Program 2020;2020:389-94. [PMID: 33275748 DOI: 10.1182/hematology.2020000123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Sun C, Armstrong MJ. Treatment of Parkinson's Disease with Cognitive Impairment: Current Approaches and Future Directions. Behav Sci (Basel) 2021;11:54. [PMID: 33920698 DOI: 10.3390/bs11040054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
25 Reed X, Schumacher-Schuh A, Hu J, Bandres-Ciga S. Advancing Personalized Medicine in Common Forms of Parkinson's Disease through Genetics: Current Therapeutics and the Future of Individualized Management. J Pers Med 2021;11:169. [PMID: 33804504 DOI: 10.3390/jpm11030169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Galper J, Balwani M, Fahn S, Waters C, Krohn L, Gan-Or Z, Dzamko N, Alcalay RN. Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease. Mov Disord 2021;36:1451-5. [PMID: 33570220 DOI: 10.1002/mds.28525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
27 Behl T, Kaur G, Fratila O, Buhas C, Judea-Pusta CT, Negrut N, Bustea C, Bungau S. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review. Transl Neurodegener 2021;10:4. [PMID: 33446243 DOI: 10.1186/s40035-020-00226-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 16.0] [Reference Citation Analysis]
28 Behl T, Kaur G, Fratila O, Buhas C, Judea-pusta CT, Negrut N, Bustea C, Bungau S. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review. Transl Neurodegener 2021;10. [DOI: 10.1186/s40035-020-00226-x] [Reference Citation Analysis]
29 Matar E, McCarter SJ, St Louis EK, Lewis SJG. Current Concepts and Controversies in the Management of REM Sleep Behavior Disorder. Neurotherapeutics 2021;18:107-23. [PMID: 33410105 DOI: 10.1007/s13311-020-00983-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
30 Muñoz SS, Petersen D, Marlet FR, Kücükköse E, Galvagnion C. The interplay between Glucocerebrosidase, α-synuclein and lipids in human models of Parkinson's disease. Biophys Chem 2021;273:106534. [PMID: 33832803 DOI: 10.1016/j.bpc.2020.106534] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
31 Montine TJ, Bukhari SA, White LR. Cognitive Impairment in Older Adults and Therapeutic Strategies. Pharmacol Rev 2021;73:152-62. [PMID: 33298513 DOI: 10.1124/pharmrev.120.000031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
32 Tan AH, Hor JW, Chong CW, Lim SY. Probiotics for Parkinson's disease: Current evidence and future directions. JGH Open 2021;5:414-9. [PMID: 33860090 DOI: 10.1002/jgh3.12450] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
33 Angelopoulou E, Paudel YN, Villa C, Piperi C. Arylsulfatase A (ASA) in Parkinson's Disease: From Pathogenesis to Biomarker Potential. Brain Sci 2020;10:E713. [PMID: 33036336 DOI: 10.3390/brainsci10100713] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
34 Alcalay RN, Wolf P, Chiang MSR, Helesicova K, Zhang XK, Merchant K, Hutten SJ, Scherzer C, Caspell-Garcia C, Blauwendraat C, Foroud T, Nudelman K, Gan-Or Z, Simuni T, Chahine LM, Levy O, Zheng D, Li G, Sardi SP; Parkinson’s Progression Markers Initiative. Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. Ann Clin Transl Neurol 2020;7:1816-30. [PMID: 32888397 DOI: 10.1002/acn3.51164] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
35 Colombo D, Pnevmatikou P, Melloni E, Keywood C. Therapeutic innovation in Parkinson's disease: a 2020 update on disease-modifying approaches. Expert Rev Neurother 2020;20:1047-64. [PMID: 32758042 DOI: 10.1080/14737175.2020.1800454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
36 Li D, Mastaglia FL, Fletcher S, Wilton SD. Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era. Med Res Rev 2020;40:2650-81. [PMID: 32767426 DOI: 10.1002/med.21718] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
37 Marras C, Chaudhuri KR, Titova N, Mestre TA. Therapy of Parkinson's Disease Subtypes. Neurotherapeutics 2020;17:1366-77. [PMID: 32749651 DOI: 10.1007/s13311-020-00894-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]